

Curriculum vitae



Personal:

Name Ji Hyun Lee, MD.
Address Division of Hematology-Oncology,
Department of Internal Medicine
Dong-A University Hospital
26 Daesingongwon-ro, Seo-gu, Busan, 49201, Korea,
Republic of
TEL: 82-51-240-5044
FAX: 82-51-246-5044
e-mail: hidrleejh@dau.ac.kr

Education:

Premedical school

2000.3.-2002.2. College of Medicine, Dong-A University, Busan, Korea, Republic of

Medical college

2002.3.-2006.2. College of Medicine, Dong-A University, Busan, Korea, Republic of
M.D. licensed (Mar./2006)

2005.8. Clerkship, Harvard Medical School, Boston, MA, USA

Postgraduate school:

2008.3.-2010.2. Dong-A University, Busan, Republic of Korea M.S.

2010.3.-2013.2. Dong-A University, Busan, Republic of Korea Ph.D.

Training:

2006.3.-2007.2. Internship, Dong-A University Hospital, Busan, Korea, Republic of

2007.3.-2011.2. Residency, Department of Internal Medicine,
Dong-A University Hospital, Busan, Korea, Republic of

2011.3.-2014.2. Clinical fellowship, Department of Internal Medicine,
Dong-A University Hospital, Busan, Korea, Republic of

Position held:

2014.3.-present Assistant Professor, Department of Internal Medicine,
Dong-A University Hospital, Busan, Korea, Republic of

2020.3.-present Associate Professor, Department of Internal Medicine,
Dong-A University Hospital, Busan, Korea, Republic of

Certificates:

- Korean Medical License (No. 89688)
- Korean Board of Internal Medicine (No. 13043)
- Korean Board of Hematology-oncology (No.6-13-473)

Professional Societies:

- 2011-present: Korean Society of Hematology-Member
- 2019-2020: International Conference of Korean Society of Hematology
 - Scientific committee executive secretary
- 2011-present: Korean Society of Blood and Marrow Transplantation-Member
- 2017-present: International Conference of Blood and Marrow Transplantation
 - Scientific committee member
- 2017-present: Scientific committee member of Korean Blood and Marrow Transplantation Registry
- 2011-present: Korean Society of Thrombosis and Hemostasis-member
- 2011-present: Korean Society of Internal Medicine-Member
- 2016-present: American Society of Hematology-Member

Awards:

1. Best oral presentation award (2019 ICKSH)
 - “Real world experience of carfilzomib, and dexamethasone versus pomalidomide-based combination chemotherapy after 2nd-Line therapies in RRMM”
2. Best scholarship award (2017 Korean Society of Thrombosis and Hemostasis)
 - “Venous thromboembolism following L-asparaginase treatment for lymphoid malignancies in Korea”
3. Best paper award (2014 Korean society of hematology)
 - “Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamide”
4. Best scholarship award (2012 Korean Society of Oncology)
 - “Predictive Value of In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay in Advanced Gastric Cancer Patients Who Received Oral 5-Fluorouracil after Curative Resection”

Grant:

- Korean National Research Fund (NRF-2017R1C1B5014853).
 - “A study of pathomechanism of microtubule inhibitor induced peripheral neuropathy”

**** First or corresponding authored publications**

1. Lee JH, Park Y, Ka-Won Kang K-W, et al. Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial. *Ann Hematol*. 2021 Aug;100(8):2051-2059.
2. Lee JH, Kim S-H. Treatment of relapsed and refractory multiple myeloma. *Blood Res*. 2020 Jul 31;55(S1):S43-S53.
3. Huh SJ, Kim SH, Kim HJ, Han JY, Lim H, Lee JH. Philadelphia-positive mixed phenotype acute leukemia presenting with PML-RARalpha fusion transcript without t(15;17) on cytogenetic studies. *Blood Res* 2018;53:256-60.
4. Lee JH, Lee J, Yhim HY, Oh D, Bang SM. Venous thromboembolism following L-asparaginase treatment for lymphoid malignancies in Korea. *J Thromb Haemost* 2017;15:655-61.
5. Lee JH, Kim SH, Oh SY, et al. Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer. *Korean J Intern Med* 2013;28:314-21.
6. Lee JH, Kwon KA, Lee S, et al. Multicentric Castleman disease complicated by tumor lysis syndrome after systemic chemotherapy. *Leuk Res* 2010;34:e42-5.
7. Lee JH, Kwon KA, Lee S, et al. Incidence and clinical characteristics of clonal cytogenetic abnormalities of acquired aplastic anemia in adults. *Korean J Hematol* 2010;45:242-6.
8. Lee JH, Choi J, Kwon KA, et al. Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamide. *Korean J Hematol* 2010;45:102-8.

**** Co-authored publications**

1. Hong J, Ahn S-Y, Leea YJ, et al. Updated recommendations for the treatment of venous thromboembolism. *Blood Res*. 2021 Mar 31;56(1):6-16.
2. Yi JH, Kim SJ, Yoon DH, et al. Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis. *Cancer Commun (Lond)*. 2021 Mar;41(3):275-278.
3. Huh SJ, Oh SY, Lee S, et al. *Oncol Lett*. Mutational analysis of extranodal marginal zone lymphoma using next generation sequencing. 2020 Nov;20(5):205.
4. Lee SS, Jung SH, Do YR, et al. Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia. *Yonsei Med J*. 2020 Jun;61(6):452-459.
5. Lee GB, Jiwon Choi JW, Nam Y-J, et al. Identification and characterization of saikosaponins as antagonists of transient receptor potential A1 channel. *Phytother Res*. 2020 Apr;34(4):788-795.
6. Kim DJ, Kim T, Jeong J-Y, et al. Poor prognostic impact of high serum ferritin levels in patients with a lower risk of diffuse large B cell lymphoma. *Int J Hematol*. 2020 Apr;111(4):559-566.

7. Kim YS, Ji JH, Oh SY, et al. A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin Toxicities *Oncologist*. 2020 Jan;25(1):e186-e193.
8. Jung SH, Lee SR, Yang DH, et al. Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party. *Ann Hematol* 2019;98:151-8.
9. Yhim HY, Park Y, Han YH, et al. A risk stratification model for nodal peripheral T-cell lymphomas based on the NCCN-IPI and posttreatment Deauville score. *Eur J Nucl Med Mol Imaging* 2018;45:2274-84.
10. Sohn SK, Moon JH, Lee IH, et al. No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome. *Korean J Intern Med* 2018;33:1194-202.
11. Oh SY, Kim WS, Kang HJ, et al. Treating synchronous bilateral ocular adnexal marginal zone lymphoma: the consortium for improving survival of lymphoma study. *Ann Hematol* 2018;97:1851-7.
12. Kim HJ, Seo JW, Roh MS, Lee JH, Song KH. Clinical features and prognosis of Asian patients with acral lentiginous melanoma who have nodal nevi in their sentinel lymph node biopsy specimen. *J Am Acad Dermatol* 2018;79:706-13.
13. Seo J, Kim WS, Kim JS, et al. Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial. *Blood Res* 2017;52:200-6.
14. Lee S, Kim DH, Oh SY, et al. Clinicopathologic significance of tumor microenvironment CD11c, and FOXP3 expression in diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy. *Korean J Intern Med* 2017;32:335-44.
15. Lee S, Huh SJ, Oh SY, et al. Clinical significance of coagulation factors in operable colorectal cancer. *Oncol Lett* 2017;13:4669-74.
16. Lee HS, Min CK, Lee JJ, et al. The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea. *Ann Hematol* 2016;95:911-9.
17. Kwon KA, Yun J, Oh SY, et al. Clinical Significance of Peroxisome Proliferator-Activated Receptor gamma and TRAP220 in Patients with Operable Colorectal Cancer. *Cancer Res Treat* 2016;48:198-207.
18. Jo JC, Choi Y, Shin HJ, et al. Peripheral T cell lymphomas in elderly patients: a retrospective analysis from the Hematology Association of South East Korea (HASEK). *Ann Hematol* 2016;95:619-24.

19. Lee HJ, Kim DH, Lee S, et al. Analysis of factors affecting hemorrhagic diathesis and overall survival in patients with acute promyelocytic leukemia. *Korean J Intern Med* 2015;30:884-90.
20. Kim C, Lee HS, Min CK, et al. The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea. *Korean J Intern Med* 2015;30:675-83.
21. Lee HS, Kim K, Yoon DH, et al. Clinical factors associated with response or survival after chemotherapy in patients with Waldenstrom macroglobulinemia in Korea. *Biomed Res Int* 2014;2014:253243.
22. Kim DH, Oh SY, Kim SY, et al. DNA ligase4 as a prognostic marker in nasopharyngeal cancer patients treated with radiotherapy. *Asian Pac J Cancer Prev* 2014;15:10985-9.
23. Oh SY, Kwon HC, Kim SH, et al. The relationship of vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer. *BMC Cancer* 2013;13:43.
24. Lee S, Oh SY, Kim SH, et al. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy. *BMC Cancer* 2013;13:350.
25. Yoon HH, Huh SJ, Lee JH, et al. Should we still use Camitta's criteria for severe aplastic anemia? *Korean J Hematol* 2012;47:126-30.
26. Oh SY, Kwon HC, Kim SH, et al. Prognostic significance of serum levels of vascular endothelial growth factor and insulin-like growth factor-1 in advanced gastric cancer patients treated with FOLFOX chemotherapy. *Chemotherapy* 2012;58:426-34.
27. Lee S, Kwon HC, Kim SH, et al. Identification of genes underlying different methylation profiles in refractory anemia with excess blast and refractory cytopenia with multilineage dysplasia in myelodysplastic syndrome. *Korean J Hematol* 2012;47:186-93.
28. Kwon HC, Kim SH, Oh SY, et al. Clinicopathologic significance of expression of nuclear factor-kappaB RelA and its target gene products in gastric cancer patients. *World J Gastroenterol* 2012;18:4744-50.
29. Kwon HC, Kim SH, Oh SY, et al. Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. *Biomarkers* 2012;17:216-22.
30. Lee DH, Oh SY, Lee YR, et al. A Phase II Study of Modified FOLFOX4 for Colorectal Cancer Patients with Peritoneal Carcinomatosis. *Cancer Res Treat* 2011;43:225-30.
31. Kim SH, Lee JH, Choi J, et al. Improvement of the WHO classification-based prognostic scoring system (WPSS) by including age for Korean patients with the myelodysplastic syndrome. *Leuk Res* 2010;34:1589-95.